Advertisement
Advertisement
OCUL
Ocular Therapeutix, Inc.
9.16
USDSponsored
-0.12
-1.29%
May 12, 15:59 UTC -4
Closed
Pre-Market
9.16
0.00
0.00%
OCUL Earnings Reports
Positive Surprise Ratio
OCUL beat 19 of 42 last estimates.
45%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$13.45M
/-$0.38
Implied change from Q1 26 (Revenue/ EPS)
+24.67%
/-5.00%
Implied change from Q2 25 (Revenue/ EPS)
-0.10%
/-2.56%
Ocular Therapeutix, Inc. earnings per share and revenue
On May 05, 2026, OCUL reported earnings of -0.40 USD per share (EPS) for Q1 26, missing the estimate of -0.31 USD, resulting in a -25.59% surprise. Revenue reached 10.79 million, compared to an expected 12.85 million, with a -16.08% difference. The market reacted with a -0.61% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 13.45 million USD, implying an decrease of -5.00% EPS, and increase of 24.67% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-53.85%
Relmada Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.22
Surprise
-10.61%
Perspective Therapeutics, Inc.
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.30
Actual
-$0.25
Surprise
+17.25%
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
Inhibikase Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.10
Surprise
+8.59%
Achieve Life Sciences, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.19
Surprise
+39.59%
Tonix Pharmaceuticals Holding Corp.
Report Date
May 11, 2026 For Q1 26
Estimate
-$2.48
Actual
-$2.93
Surprise
-18.05%
Heron Therapeutics, Inc.
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.01
Actual
-$0.04
Surprise
-161.44%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.41
Surprise
-5.92%
Fractyl Health, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.34%
FAQ
What were Ocular Therapeutix, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ocular Therapeutix, Inc. reported EPS of -$0.40, missing estimates by -25.59%, and revenue of $10.79M, -16.08% below expectations.
How did the market react to Ocular Therapeutix, Inc.'s Q1 2026 earnings?
The stock price moved down -0.61%, changed from $9.77 before the earnings release to $9.71 the day after.
When is Ocular Therapeutix, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Ocular Therapeutix, Inc.'s next earnings report?
Based on 9
analysts, Ocular Therapeutix, Inc. is expected to report EPS of -$0.38 and revenue of $13.45M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement